FilingReader Intelligence
Actinogen reports $14.7m loss, advances Alzheimer's trial
August 25, 2025 at 10:17 AM UTC•By FilingReader AI
Actinogen Medical reported a net loss of $14.7m for FY2025, driven by clinical trial investments. The company reached the 100th participant in its XanaMIA Phase 2b/3 Alzheimer's trial, with interim results expected January 2026.
Positive depression trial results from XanaCIDD Phase 2a were announced. Actinogen secured funding to mid-late 2026.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
ASX:ACW•Australian Securities Exchange
News Alerts
Get instant email alerts when Actinogen Medical Limited publishes news
Free account required • Unsubscribe anytime